Io­n­is launch­es an ear­ly-stage tau drug study for Alzheimer’s, pick­ing up $10M from Bio­gen

Af­ter amy­loid be­ta, the sec­ond big tar­get in Alzheimer’s dis­ease cen­ters on tox­ic ac­cu­mu­la­tions of tau, pos­si­bly work­ing hand-in-hand with a-be­ta to fry peo­ple’s mem­o­ries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.